CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
晚期结直肠癌的过继性 T 细胞治疗：一项系统评价
英文原题：Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review.
查看英文原题
Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
结直肠癌（CRC）是美国癌症相关死亡的第二大原因。对于绝大多数晚期 CRC 患者（即转移性肿瘤无法切除的患者），治疗为姑息性，通常包括化疗、生物治疗和/或免疫检查点抑制。近年来，利用机体自身免疫系统识别并靶向癌症的过继性 T 细胞治疗（ACT）的应用日益普遍。遗憾的是，尽管 ACT 在血液系统恶性肿瘤的治疗中取得了成功，但在晚期 CRC 中疗效较差，部分原因是缺乏有效的免疫浸润。本系统综述旨在总结 ACT 在晚期 CRC 中疗效和安全性的当前数据。我们报告 ACT 在晚期 CRC 患者中耐受性良好。接受 ACT 的晚期 CRC 患者中有利的生存估计显示了这一新型治疗模式的希望。然而，仍需额外的 I/II 期临床试验来确定 ACT 在 CRC 患者中的疗效和安全性。
展开英文摘要原文
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the US. For the vast majority of patients with advanced CRC (ie, for those in whom metastatic tumors are unresectable), treatment is palliative and typically involves chemotherapy, biologic therapy, and/or immune checkpoint inhibition.
In recent years, the use of adoptive T-cell therapy (ACT), leveraging the body's own immune system to recognize and target cancer, has become increasingly popular. Unfortunately, while ACT has been successful in the treatment of hematological malignancies, it is less efficacious in advanced CRC due in part to a lack of productive immune infiltrate. This systematic review was conducted to summarize the current data for the efficacy and safety of ACT in advanced CRC.
We report that ACT is well tolerated in patients with advanced CRC. Favorable survival estimates among patients with advanced CRC receiving ACT demonstrate promise for this novel treatment paradigm.
However, additional stage I/II clinical trials are needed to establish the efficacy and safety of ACT in patients with CRC.
论文信息
- 作者
- Juat DJ、Hachey SJ、Billimek J、Del Rosario MP、Nelson EL、Hughes CCW、Zell JA
- 第一作者单位
- Department of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA, USA.United States
- 通讯作者单位
- Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, CA, USA.United States
- 文献类型
- 美国 NIH 资助研究 · 非美国政府资助研究 · 系统综述
- 期刊
- The oncologist2022 Mar 11
- 原文标识
- PubMed 35274719 · DOI 10.1093/oncolo/oyab038
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →